No description available.

Seminal plasma (SP) is the microenvironment of spermatozoa whose composition reflects semen quality and constitutes an excellent source for detecting non-invasive biomarkers. This study characterizes good vs. poor quality semen using seminal extracellular vesicles coupled proteins and miRNA. Fresh boar semen samples were screened, centrifuged, and SP supernatants were collected for near-infrared spectroscopy (NIRS) analysis. EVs were extracted from SP (SP-EVs), characterized, and those of extremely poor or good sperm quality groups were subjected to proteomics and small RNA sequencing. Significant differences were set for P

Preterm birth (<37 weeks) is the world’s principal cause of death of children <5 years of age. Bronchopulmonary dysplasia (BPD) is the most common complication of preterm birth. BPD is characterized by an arrest in alveolar and vascular development within the lung. It is a multifactorial disease, caused by a combination of supplemental oxygen, mechanical ventilation, and inflammation. BPD is also an independent risk factor for abnormal neurodevelopment. The link between BPD and abnormal neurodevelopment is poorly understood and there are currently no effective cures for these complications. We hypothesized that a crucial cell population for brain development, i.e., the neural progenitor cell (NPC) is functionally impaired in BPD and that this impairment is associated with abnormal neurodevelopment. Based on our previous findings, we also predicted that human umbilical cord-mesenchymal stromal cell (UC-MSC) extracellular vesicles (EVs), could mitigate both the lung and brain injuries in experimental BPD. We utilized several animal models of BPD, across multiple species, to determine the effects of hyperoxia, mechanical ventilation, and inflammation on the developing lungs and brain. We also utilized UC- MSC therapy to mitigate these injuries. We discovered that hyperoxia exposure damages the developing lungs as well as the brain, leading to cerebrovascular and NPC impairments, as well as reduced neurogenesis. These impairments were associated with neurobehavioural deficits in adulthood. Furthermore, we found that inflammation in combination with mechanical ventilation and hyperoxia also impairs NPC function. Importantly, we demonstrated that UC-MSC EVs can reduce inflammation, improve vascular growth, restore lung growth, and mitigate impairments in NPC self-renewal. This work highlights novel mechanisms of BPD-associated abnormal neurodevelopment and offers potential regenerative medicine therapies to alleviate these outcomes for this vulnerable population.

No description available.

No description available.

No description available.

Layer 3 (L3) pyramidal neurons are involved in intrinsic and extrinsic corticocortical communications that are integral to area specific cortical functions. The functional and morphological properties of these neurons are altered in the lateral prefrontal cortex (LPFC) of aged rhesus monkeys, changes which parallel the decline of working memory (WM) function. What is not yet understood is the time course of these neuronal alternations during the aging process, or the impact of neuronal changes on the function of local networks that underlie WM. By comparing the properties of L3 pyramidal neurons from the LPFC of behaviorally characterized rhesus monkeys over the adult lifespan using whole cell patch clamp recordings and neuronal reconstructions, the present dissertation demonstrates that WM impairment, neuronal hyperexcitabilty and spine loss begin in middle age. We use bump attractor models to predict how empirically observed changes affect performance on the Delayed Response Task and Delayed Recognition Span Task (spatial). The performance of both models is affected much more by neuronal hyperexcitability than by synapse loss. In a separate study, we examine pathological changes of L3 pyramidal neurons in the perilesional ventral premotor cortex following acute ischemic injury to the primary motor cortex. Neurons from lesioned monkeys exhibit hyperexcitability and changes the excitatory:inhibitory synaptic balance in favor of inhibition. As oxidative stress and inflammation are known to exacerbate both age-related and injury-induced neuronal pathology, we characterize neuronal properties in both conditions after administering therapeutic interventions which target inflammatory pathways and which have previously been shown to ameliorate behavioral deficits. Chronic dietary curcumin treatment dampens neuronal hyperexcitability in middle-aged subjects, but the neuronal changes are not correlated with WM improvements. Treatment with mesenchymal-derived extracellular vesicles lowers firing rates and restores excitatory:inhibitory synaptic balance, and importantly, these changes correlate significantly with motor function.

Extracellular vesicles are important players in cell-to-cell communication and have the potential to be used as biomarkers for decease. The mechanical properties of extracellular vesicles is an active field of research, with new methods and models being developed. In this thesis, two samples of extracellular vesicles containing different levels of membrane protein expressions are investigated using atomic force microscopy. Three models for determining stiffness are applied to the samples: the Hertz model, an adhesion angle dependent model, and the modified Canham-Helfrich model. The Hertz model indicated a higher Young’s Modulus for vesicles without membrane proteins, but with large errors. The adhesion angle dependent model did not provide high enough sensitivity to determine any difference in stiffness between the two samples. The modified Canham-Helfrich model indicated a higher bending modulus for the vesicles with membrane proteins. The results highlight the importance of taking several measurements on each vesicle, in contrast to how the method is currently applied in research. / Extracellulära vesiklar är essentiella komponenter inom cell-till-cell-kommunikation, och har potentialen att kunna användas som sjukdomsmarkörer. Extracellulära vesiklars mekaniska egenskaper är ett aktivt forskningsfält där nya experimentella metoder och teoretiska modeller är under utveckling. I den här arbetet används atomkraftsmikroskopi för att undersöka de mekaniska egenskaperna av två prover av extracellulära vesiklar med olika mängd membranproteiner. Tre modeller för att utvärdera deras styvhet tillämpas: Hertz-modellen, en adhesionsvinkelberoende modell, och den modifierade Canham-Helfrichmodellen. Hertz-modellen indikerade högre elasticitetsmodul för provet med lägre antal membranprotein, men med stora fel i mätningarna. Den adhesionsvinkelbaserade modellen var inte känslig nog att påvisa några skillnader i styvhet mellan proverna. Den modifierade Canham-Helfrich-modellen indikerade att vesiklarna med membranprotein har högre böjmodul än veiklarna utan membranprotein. Resultaten understryker att det är viktigt att göra flertalet mätningar på varje vesikel, i kontrast mot hur modellen tillämpas i dagsläget.

Extracellular Vesicles (EVs) are small membranous particles secreted by the cells. They play an important role in intercellular communication and can transport a variety of biomolecules, including proteins, lipids, and nucleic acids, to target cells. The scientific community recently considered EVs attractive candidates for developing targeted drug delivery systems (DDSs), given their biocompatibility, low immunogenicity, stability in biofluids, and capability to cross biological barriers. Most studies have shown the feasibility of incorporating desired moieties at the EV surface through the genetic modification of EV-producing cells, exploiting the fusion with proteins enriched at the EV membrane. Tetraspanins are transmembrane proteins enriched in EVs, already exploited for EV isolation or tracking upon fusion with fluorescent reporters. CD81 is a well-characterized tetraspanin with ubiquitous protein expression, overexpression tolerance and a limited number of encoded protein isoforms with respect to other EV-associated tetraspanins. Here, I have explored a CD81-based approach for EV targeting. CD81, in full-length or truncated form, was used to guide the expression into EVs of an anti-HER2 moiety, namely the light chains of trastuzumab, within three different constructs, including turbo-GFP (tGFP) as a reporter: CD81-tGFP as master control, CD81-antiHER2-tGFP and CD81delta-antiHER2-tGFP. The first part of the project was dedicated to the characterization of chimeric proteins at cellular and vesicular levels. CD81-based constructs were successfully expressed in HEK239T cells with a preferential enrichment in organelle fractions, underlying the expected involvement in the intracellular vesicular trafficking. Next, chimeric proteins were also found in the derived EVs, with a similar expression trend, corroborated by imaging flow cytometry. Nanoparticle tracking analysis and cryogenic electron microscopy acquisitions confirmed that CD81-fusion proteins boosted EV release without altering the size distribution. Subsequently, I tested the binding capacity of the chimeric proteins to HER2 receptor through orthogonal techniques, such as AlphaLISA and immunoprecipitation. Confocal imaging, also on live cells, confirmed EV internalization into breast cancer cells, depending on the recipient cell type and the presence of HER2 receptor. Moreover, chimeric EVs loaded with doxorubicin were able to mediate a concentration-dependent cytotoxic effect on recipient breast cancer cells. Of note, messenger RNA provided a valuable readout of the in vivo delivery capability of the CD81-engineered EVs, since detected by digital droplet PCR in breast cancer tumour xenografts from mice treated with chimeric EVs. The results presented in this thesis highlighted the feasibility of using CD81 fusion proteins for cell targeting and cargo delivery, ultimately opening new perspectives for the development of EV-based therapeutics.

Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by arterial pruning, occlusive vascular remodeling, and inflammation contributing to increased pulmonary vascular resistance with resultant right heart failure. Endothelial cell (EC) injury and apoptosis are commonly considered triggers for PAH, the mechanisms leading from injury to complex arterial remodeling are incompletely understood. While current therapies can improving symptoms, with the exception of parenteral prostacyclin, they do not significantly prolong transplant free survival. As well, there are no therapies that can regenerate the damaged lung short of transplantation. In this project, I sought to both advance the understanding of disease pathogenesis and explore regenerative therapeutic options for PAH. To this end, I first employed single cell RNA sequencing (scRNA-seq) at multiple time points during the Sugen 5416 (SU) – chronic hypoxia (CH) model of PAH, to provide new insights into PAH pathogenesis both during onset and progression of disease. We also employed microCT analysis to visualize and quantify the arterial pruning associated with PH and found significant loss up to 65% of the healthy arteriolar volume in this model. Through scRNA-seq analysis performed at four timepoints spanning the onset and progression of disease, two disease-specific EC cell types emerged as key drivers of PAH pathogenesis. The first was the emergence of capillary ECs with a de-differentiated gene expression profile, which we termed dedifferentiated capillary (dCap) ECs, with enrichment for the Cd74 gene. Interestingly, RNA velocity analysis suggested that these cells may be undergoing endothelial to mesenchymal transition during PAH development. At later times, a second arterial EC population became apparent, which we termed activated arterial ECs (aAECs), since it uniquely exhibited persistently elevated levels of differential gene expression consistent with a migratory, invasive and proliferative state. Interestingly, the aAECs together with the smooth muscle (SM)-like pericytes, a population which was also greatly expanded in PAH, expressed Tm4sf1, a gene previously associated with a number of cancers and abnormal cell growth. Furthermore, by immunostaining, TM4SF1 was found to be spatially localized to sites of complex and occlusive arterial remodeling, associated with both endothelial cells and pericytes in these lesions, suggesting an important role for the aAECs and SM-like pericytes in arterial remodeling and PH progression. Together, these findings suggest that aAECs, dCap ECs, and SM-like pericytes are emerging cell populations responsible for lung arterial remodeling in PAH, which drives disease progression, and that TM4SF1 may be a novel therapeutic target for this disease. As a first step in trying to develop approaches to regenerate lung arterial bed that is lost in PAH, we investigated the potential role of endothelial colony forming cells (ECFCs) and mesenchymal stromal cell (MSC) derived extracellular vesicles (EVs) as novel therapeutics, on the premise that these stem/progenitor cells would stimulate lung regeneration by mainly paracrine mechanisms. Additionally, we used biomaterials to microencapsulate cells and EVs to improve their local delivery and retention. While ECFCs were found to be ineffective in treating the monocrotaline model on their own, they were poorly retained in the lung and microencapsulation of ECFCs led to enhanced lung delivery within the first 72 hours, with resultant hemodynamic improvements in this model of PAH. MSCs are well known to be immunomodulatory and proangiogenic, largely acting through paracrine mechanisms, including by the release of EVs. Yet, following intravenous administration, nano sized EVs are rapidly cleared from circulation, potentially limiting their therapeutic potential. I adapted our microencapsulation strategy for EVs, and demonstrated significantly greater retention of microgel-loaded EVs were within the lung, resulting in enhanced local cell uptake. Interestingly, the hydrogel used for microencapsulation induced a local immune response which made it unsuitable for testing any potential therapeutic benefits of MSC-EVs in this study. Nonetheless, this work demonstrated proof-of-principle for the utility of microencapsulation as a strategy to enhance EV lung delivery. Overall, this work has identified novel lung cell populations (aAECs, dCap ECs, SM-like pericytes) driving arterial remodeling associated with PH progression, demonstrated the potential of ECFCs as a regenerative cell for the treatment of PAH, and illustrated the utility of microencapsulation as a tool to enhance lung targeting of both cells and EVs.